Search

Displaying results 1061 - 1070 of 2815 in total
  1. Drug

    Coffea arabica seed, roasted

    go.drugbank.com/drugs/DB15603
    Approved

    Coffea arabica seed, roasted allergenic extract is used in allergenic testing.

    Mixtures: Gel
  2. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography. … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins.

  3. Drug

    Brimapitide

    go.drugbank.com/drugs/DB15231
    Investigational

    Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).

  4. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Mixtures: Alahist PE, Ala-hist PE
  5. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.

  6. Drug

    Kojic acid

    go.drugbank.com/drugs/DB01759
    Approved

    Mixtures: Eye Gel
  7. Drug

    Honey

    go.drugbank.com/drugs/DB14242
    ApprovedInvestigational

    Honey is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Gel
  8. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  9. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    [A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  10. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [A262929] On January 3, 2024, fidanacogene elaparvovec was approved by Health Canada under the brand name BEQVEZ for the treatment of adults with moderately severe to severe hemophilia B (congenital